Third Harmonic Bio, Inc. Stock Price

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.